Allo-SCT is the only potentially curative regimen for myelodysplastic syndromes (MDSs), but it is associated with a high relapse risk. The role of chimerism analysis for prediction of relapse is yet to be determined. To assess the clinical usefulness of mixed chimerism (MC) for predicting hematological relapse, 75 consecutively transplanted patients with MDS were analyzed with regard to lineagespecific chimerism, encompassing CD33 þ cells in peripheral blood (PB, n ¼ 49) and CD34 þ cells in BM (n ¼ 35). A cutoff of 5% recipient cells was used to discriminate complete donor chimerism from MC. A total of 19 patients (25%) experienced hematological relapse after a median of 5 (1-31) months. Sensitivity for detection of relapse was 59% for CD33 þ PB cells and 92% for CD34 þ BM cells with corresponding specificities of 91% and 65%. CD34 þ BM cells were analyzed before relapse in seven patients, five of whom showed MC at a median of 2.5 (0.5-7) months before relapse. In contrast, 8 of 18 patients showed MC involving CD33 PB with a median of one month (0.5-2) before relapse. Here, we provide a model for early detection of relapse after SCT in MDS, in which serial characterization of both CD33 þ PB cells and CD34 þ BM cells gives an opportunity for early treatment before overt relapse.
Introduction
The myelodysplastic syndromes (MDSs) are a group of heterogeneous clonal stem cell disorders characterized by apoptosis of marrow progenitors, leading to peripheral cytopenia, and a high propensity for leukemic transformation arising from the stem cell population that escapes apoptotic control. The 'stemness' of this disease implies a high degree of resistance to chemotherapy, and a cure by conventional induction chemotherapy is exceedingly uncommon. 1 Patients with MDS may be cured by allogeneic hematopoietic SCT, but this treatment is feasible only for a fraction of the patient population owing to high age, comorbidity or lack of a suitable donor. The long-term survival rate after transplantation ranges from 25 to 45%. [2] [3] [4] [5] [6] Despite advances in transplantation technology, considerable mortality and risk of relapse still remain. Transplantation-related mortality after myeloablative conditioning (MAC) and reduced-intensity conditioning (RIC) ranges from 22 to 32%, and the relapse rate ranges from 22 to 45%, respectively. 2 The risk of transplantationrelated mortality is inversely related to the risk of relapse, 2 and better tools to predict and, hence, effectively treat early relapse are highly desirable.
Known risk factors for unfavorable outcome after SCT for MDS encompass blast counts X5%, 3, 7 high-risk karyotype, 8, 9 older age, 3, 5, 7, 10 low platelet count, 3 therapyrelated MDS, 10 transfusion dependency, 6 comorbidity 11 and elevated ferritin values. 12 The International Prognostic Score System (IPSS) 10, 13 and the recently established World Health Organization (WHO)-based Prognostic Score System 6, 14 have been shown to be able to predict the outcome after allo-SCT. 3, 9, 10 SCT is indicated for patients with IPSS int-2 and high. For patients with IPSS int-1, SCT can be considered after individual assessment. 15 Chimerism analysis is an important tool for assessment of the origin of hematopoietic cells after SCT. Discrimination between donor-and recipient-derived hematopoiesis allows the evaluation of engraftment. In chronic myeloid leukemia, it was reported early that mixed chimerism (MC) increases the risk of relapse. 16 In acute leukemia, the association between MC and relapse is more controversial, even though several studies have shown such an association. [17] [18] [19] Lineage-specific analysis seems to be a more sensitive method than analysis of whole blood. 17, [19] [20] [21] Chimerism analysis of peripheral blood (PB) and BM cells has never been evaluated specifically for patients with MDS. As MDS is characterized by an increase in immature cells in BM and a decrease in differentiated cells in PB, we hypothesize that a relapse would first be detected in BM.
In the present study, we evaluated the clinical impact of lineage-specific chimerism analysis of blood and BM in 75 consecutive patients with MDS after SCT. We found that serial characterization of the combination of CD33 þ cells in PB and CD34 þ cells in BM enables the early detection of relapse with optimal sensitivity and specificity. Table 1 .
Methods

Patients
Conditioning regimen
The MAC regimen consisted of CY at 60 mg/kg on 2 consecutive days (days À5 and À4, or À4 and À3) combined with either single-dose TBI or fractionated TBI (3 Gy for 4 consecutive days) or Bu (4 mg/kg/day Â 4). 22 In 11 cases, CY and Bu were combined with melphalan. RIC included fludarabine at 30 mg/m 2 /day for 6 days, combined with Bu at 4 mg/kg/day for 2 days, or with CY at 60 mg/kg for 2 days. Three patients received a combination of fludarabine and treosulphan (14 g/m 2 Â 3). One patient received the combination of fludarabine þ Bu þ cytarabin and one patient received fludarabine þ CY þ TBI (6 Gy). 23 Altogether, 41 and 32 patients received MAC and RIC, respectively. Information about the exact type of conditioning was missing for two patients. Median age in the MAC and RIC groups was 23.5 years (range 0-57) and 55 years (range 27-67), respectively.
Immunosuppression
In the majority of patients, CsA combined with four doses of MTX was given as prophylaxis against GVHD (Table 1) . 24 Three patients received a combination of tacrolimus and sirolimus. 25 One patient received CsA combined with prednisone, and one patient received CsA combined with mycophenolate mofetil. The combination thymoglobulin/OKT3/alemtuzumab was given before transplantation in all patients receiving grafts from unrelated donors and to some patients who received grafts from human leukocyte antigen-identical siblings. 26 Pre-transplantation risk factors for relapse A multivariate analysis was performed, analyzing possible risk factors for relapse known before transplantation. The variables included were age, sex, classification according to the WHO at the time of SCT, karyotype, IPSS at diagnosis, ferritin value, transfusion dependency, duration of disease and MAC vs RIC.
Chimerism analysis PCR amplification of variable numbers of tandem repeats was used to evaluate various degrees of donor and recipient chimerism in CD33 þ cells enriched from PB, and CD33 þ and CD34 þ cells from BM, using immunomagnetic beads (Dynal, Oslo, Norway) as previously described. 18 Since April 2005, a real-time PCR method based on singlenucleotide polymorphism was used for chimerism analysis as previously described. 27 Chimerism analysis started in 1997, but until 2002 it was used as an experimental method without a fixed assessment routine. It was implemented in clinical routine in 2001, and from that year assessment of chimerism status was performed at 3, 6 and 12 months after transplantation. In addition, chimerism status has been analyzed outside this schedule on clinical indication. During the whole time period, cell separation has been used, enabling analysis of CD34 In patients for whom the results of chimerism analysis were available within 3 months before hematological relapse, sensitivity and specificity for MC to predict hematological relapse, defined by BM morphology, were calculated. Two different cutoffs for MC were used: 5 and 10% of recipient cells. Calculations based on types of conditioning regimens are presented separately. Sensitivity and specificity were also calculated with decreasing amount of recipient cells defined as complete donor chimerism (CC). Furthermore, sensitivity for relapse was calculated for chimerism analysis performed exclusively before morphological relapse.
Definition of hematological relapse
As dysplasia of the myeloid cells is a common finding after the conditioning treatment, patients with dysplasia alone were not classified as relapsed. Instead, an elevated blast count with 45% blasts was used as definition of relapse.
Treatment of molecular and hematological relapse Treatment given either for a manifest hematological relapse or as a pre-emptive treatment for molecular relapse, defined as MC, was evaluated for outcome: complete hematological remission (morphological evaluation), CC (o5% of recipient cells) and survival. Optional treatment was chemotherapy, donor lymphocyte infusion (DLI) or azacytidine, and the decision was based on the clinical situation.
Statistics
The results were analyzed as of 30 June 2008, allowing for a median follow-up time of 34 months (range 2-108 months) in all subjects who were still alive. All statistical analyses were performed using Statistica 8.0 (Statsoft Inc., Tulsa, OK, USA). Times to relapse, survival so on were analyzed by the life-table method using the log-rank test, taking censored data into account. By means of Cox regression, univariate analyses were performed to discern risk factors for relapse at transplantation. Variables with P-values o0.10 in the univariate analysis were included in the following multivariate analysis, which was performed using backward elimination. Moreover, landmark analyses were performed at 3 and 6 months post-transplantation to reveal any impact of GVHD or MC on subsequent relapse. In the landmark analyses, only patients at risk for relapse were included, that is, dead and relapsed patients were excluded. In all analyses, P-values o0.05 were considered significant.
Results
Patient outcome
After a median follow-up time of 34 months (2-108), estimated OS at 5 years was 45%, with 55% survival after MAC and 34% survival after RIC (P ¼ 0.67). In all, 25% (n ¼ 19) of the patients had relapse after a median time of 5 months (1-31), 53% of whom had received RIC and 18% had received MAC (P ¼ 0.02). Transplantation-related mortality was 35% for all the patients included (n ¼ 26), 40% for patients treated with MAC and 27% for patients after RIC (P ¼ 0.39). Time plots of cumulative proportion of relapse, transplantation-related mortality and OS are shown in Figure 2 . Acute GVHD of grades I-II and III-IV occurred in 27 and 16% of the patients, respectively.
Risk factors for relapse at transplantation
By univariate analysis, only RIC was significantly associated with relapse (odds ratio ¼ 2.73 (1.09-6.87), P ¼ 0.03). By multivariate analysis, RIC (odds ratio ¼ 3.34 (1.25-8.97), P ¼ 0.02) and cytogenetics (odds ratio ¼ 1.86 (1.04-3.33), P ¼ 0.04) were significantly associated with relapse.
Landmark multivariate analysis
By univariate analysis from landmark data at 3 months, MC (CD33 þ cells, CD34 þ cells and both) was not significantly associated with relapse (P ¼ 0.31, P ¼ 0.12 and P ¼ 0.15, respectively). Neither was acute GVHD significantly associated with relapse (P ¼ 0.76). Similarly, neither MC (P ¼ 0.22, P ¼ 0,39, P ¼ 0.92) nor chronic GVHD (P ¼ 0.12) was significantly associated with relapse by univariate analysis from landmark data performed at 6 months.
Causes of death
Causes of death for non-relapsed patients were: acute GVHD (n ¼ 9), chronic GVHD (n ¼ 2), post-transplantation lymphoproliferative disease (n ¼ 2), septic shock (n ¼ 2), multiple organ failure (n ¼ 2), pneumonia (n ¼ 2), cytomegalovirus pneumonia (n ¼ 1), rejection (n ¼ 1), and cardiac failure (n ¼ 1), and unknown cause because of a missing report (n ¼ 4).
Chimerism analysis: eligible patients
Owing to the development of methodologies during the first year of this study, there were insufficient chimerism data for 13 patients regarding CD33 þ cells in PB and for 27 patients regarding CD34
þ cells in BM. Six patients were excluded because of early death and lack of adequate evaluation of BM morphology, two because of graft rejection, and two because of missing reports on BM morphology. Since 2001, treating physicians were not blinded regarding chimerism data, and evidence of MC resulted in three patients with no signs of morphological relapse in treatment with DLI having no subsequent hematological relapse. These three patients were excluded from sensitivity/specificity calculations. In total, 49 and 35 patients were eligible for chimerism evaluation regarding CD33 þ cells in PB and CD34 þ cells in BM, respectively. See Figure 1 for a breakdown of the patients who were included and excluded.
Chimerism analysis: sensitivity and specificity in predicting relapse With the use of 5% recipient cells as cutoff for discrimination of patients with MC from patients with CC, 13 of 49 patients who could be evaluated (27%) showed MC for CD33 þ cells in PB at any time point. Similarly, 19 of 35 patients (54%) showed MC regarding CD34 þ cells in BM. The sensitivities for CD33 þ cells in PB and CD34 þ cells in BM to predict relapse were 59 and 92%, respectively, while specificities were 91 and 65%. With the use of a 10% cutoff, sensitivities were 59 and 67%, and specificities were 97 and Early detection of relapse in patients with MDS after allo-SCT M Tobiasson et al 78%, respectively. Table 2 summarizes the results of the sensitivity and specificity calculations.
Sensitivities analyzed specifically for patients who had undergone MAC were 17 and 100% for CD33 þ cells and CD34 þ cells, respectively, while the specificities were 91 and 65%, respectively. Similarly, sensitivities after reduced intensity conditioning were 82 and 88% for CD33 þ cells and CD34 þ cells, respectively, while the specificities were 86 and 75%, respectively.
When patients with a decreasing amount of recipient cells were taken together with patients with CC and compared with patients with a stable or increasing amount of recipient cells, the sensitivities for CD33 þ cells in PB and CD34 þ cells in BM (5% cutoff) were 53 and 83%, respectively, while the specificities were 91 and 83%. Five patients showed a decreasing percentage of recipient CD34 þ cells in BM, one of whom had relapse. Correspondingly, one of the four patients with a decreasing percentage of recipient CD33 þ cells in PB had relapse. CD34 þ cells in BM were analyzed before hematological relapse in seven patients. Five of them (71%) showed MC at a median time of 2.5 months (0.5-7) before relapse. In contrast, 8 of 18 patients (44%) showed MC regarding CD33 þ cells in PB before relapse, with a median time of 1 month (0.5-2) before relapse. Figure 2 gives a schematic presentation of the clinical course of each patient who underwent relapse.
Treatment of hematological and molecular relapse
Hematological relapse. In all, 13 patients were given treatment owing to hematological relapse, defined by BM morphology.
Eight patients were treated with DLI. Evaluation of BM morphology after DLI was performed in four of these patients, one of whom reached CR but relapsed after 2 years. Chimerism status after DLI was evaluated in seven patients, none of whom developed CC. One patient who also received azacytidine became a long-term survivor; the other seven died after a median time of 4 months (range 2-12).
Two patients were treated with chemotherapy after hematological relapse. One reached CR, but neither patient developed CC and both died after 4 months.
Four patients were treated with azacytidine. Two of them had previous treatment with DLI. Of the three patients who could be evaluated, one reached CR and one developed CC. The patient with induced CR, who also received DLI, is still alive 1 year after introduction of azacytidine. One patient with relapse is still alive 4 months after introduction of azacytidine; the remaining two patients died after 6 and 10 months, respectively. Molecular relapse. Five patients were given pre-emptive treatment owing to molecular relapse, defined as MC without hematological relapse.
Four patients were treated with DLI in a pre-emptive setting. All four patients had MC regarding CD33 þ cells in PB. Three of these patients remained in CR, developed CC and are still alive and well after 3, 6 and 7 years, respectively. The fourth patient progressed to a hematological relapse and died.
One patient was treated with azacytidine alone in a preemptive setting. This patient did not develop CC and subsequently relapsed, but is still alive 6 months after azacytidine was introduced. 
Discussion
Despite recent advances in the transplantation setting, relapse remains a major obstacle for patients with MDS, which highlights the need for accurate post-transplantation surveillance and adoptive therapy. There is no routine method for diagnosing minimal residual disease in MDS, but chimerism analysis is frequently used for this purpose. However, it has never been evaluated specifically for this group of patients. In acute myeloid and lymphatic leukemia, there is evidence that MC can serve as a predictor of impending relapse, enabling initiation of early intervention. 17, 20, 28 In childhood acute lymphatic leukemia, it has been shown that pre-emptive adoptive immunotherapy, given as a result of MC, can prevent relapse. 24 A recent study has indicated that pre-emptive treatment with azacytidine in patients with acute myeloid leukemia and MDS can be effective. 21 The results reported here show that serial characterization of post-transplantation lineage-specific chimerism analysis offers the possibility of identifying patients with impending relapse. However, there is a great discrepancy between PB (CD33 þ cells in PB) and BM (CD34 þ cells in BM) regarding sensitivity and specificity in detecting relapse. Whereas analysis of CD34 þ cells in BM shows a very high sensitivity but lower specificity, CD33 þ cells in PB shows the opposite pattern. This indicates that analysis of CD34 þ cells in BM combined with analysis of CD33 þ cells in PB should be assessed on a regular and frequent basis, and that analysis of PB alone is not sufficient. Our results indicate that CD33 þ cells might be more sensitive after RIC than after MAC whereas CD34 þ cells is a sensitive method after both types of conditioning regimens. As the number of patients is limited when analyzing these groups separately, these results should be interpreted carefully. The results reported here also indicate that chimerism analysis can be used in predicting relapse before it can be identified by morphological examination, thus opening up a time-frame for pre-emptive treatment before the relapse becomes manifest.
The clinical implication of CC in CD34 þ cells of the BM lineage is obvious: there is a very low risk of impending relapse and thus no need for further treatment. Likewise, MC in CD33 þ cells in PB should undoubtedly lead to initiation of treatment owing to the very high risk of relapse. The situation with a CD33
À in PB/CD34 þ in BM results is, however, more difficult to interpret clinically. We propose a model (Figure 3 ) for cases in which there are no clinical signs of relapse, such as cytopenia or morphological signs, whereby chimerism analysis is repeated within 4 weeks. Increasing or stable amounts of CD34 þ recipient cells signal an impending relapse, and adoptive therapy should be initiated, whereas decreasing amounts of recipient cells would allow a watch-and-wait approach. The low sensitivity of chimerism analysis performed on PB may be a result of the disease biology of MDS, in which hematopoietic cells belonging to the MDS clone are prevented from entering the circulation owing to apoptosis. 29 Adoptive immunotherapy by DLI has been successful in the treatment of relapse in patients with chronic myeloid leukemia, but less successful in those with acute leukemia. 30 This may be a result of the disease biology, but may also be a result of earlier detection of relapse due to slower kinetics in patients with chronic myeloid leukemia and of the availability of more sensitive methods for this disease. The relapse for patients with MDS often shows slower kinetics similar to that of chronic myeloid leukemia, thus enabling adoptive treatment in an early phase of the relapse. In this study, only one patient of the eight who received DLI because of overt hematological relapse showed a possible benefit from treatment. This is in accordance with the results of a previous study. 31 Treatment with azacytidine, subsequent to relapse, in one patient resulted in long-term survival, which is similar to what was recently reported in another retrospective study. 32 To our knowledge, DLI given as pre-emptive treatment to patients with MDS has never been scientifically evaluated, however often given in the clinical setting. In our material, three of four patients who received preemptive treatment with DLI remained in remission. This can be compared with the risk of relapse of 490% in the group of patients who did not receive pre-emptive DLI. The statistical impact of this small study is limited, and further studies on pre-emptive treatment-also including new therapeutic agents such as demethylating agents-are certainly warranted.
Standard MAC showed a trend towards better OS compared with RIC, but this was not statistically significant. In multivariate analysis, there was a significant correlation between RIC and an increased risk of relapse after SCT. There may have been a selection bias, however, as patients in the RIC group were older. Thus, it is not possible to draw any clear conclusions regarding optimal conditioning regimens from this material, which also does not differ from previous reports. 2 However, in keeping with the results of the present study, MAC is the preferred preparatory treatment in patients with MDS at our unit.
As expected from previous studies, unfavorable cytogenetics was identified as a risk factor for relapse in the multivariate analysis. The multivariate analysis of risk factors in this limited cohort was generally in agreement with the results of previously published larger studies, which indicates that the chimerism analyses were performed on a well-balanced MDS material. We find no significant association between the presence of acute or chronic GVHD and relapse. As the number of patients is limited we cannot, however, exclude a GVL effect. We did not find a significant association between MC at 3 and 6 months and subsequent relapse by the landmark analyses. However, less number of patients makes it impossible to rule out that MC is a useful predictor of relapse in this setting. This needs further evaluation in lager investigations.
In conclusion, analysis of chimerism in patients with MDS is a sensitive method that enables early detection of relapse after SCT. A combined analysis of peripheral CD33 þ cells and CD34 þ marrow cells seems to give optimal sensitivity and specificity. This study may provide a rationale for treatment of relapse with adoptive treatment at an earlier time point after SCT in patients with MDS.
